Global pharmaceutical supply chains are restructuring to eliminate ongoing shortages of GLP-1 receptor agonists. Extended lead times for active pharmaceutical ingredients (APIs) continue to limit output across major markets.
Manufacturing Capital Expenditure
Drug manufacturers have committed billions toward dedicated fill-finish facilities. Contract Development and Manufacturing Organizations (CDMOs) are absorbing significant capital to expand sterile injectable capacity.
Market Expansion
As manufacturing capacity stabilizes, distribution channels are expanding into secondary global markets, driving downward pressure on wholesale pricing.